Prior to earning a PhD in natural product synthesis from University of Nottingham under the supervision of Professor Christopher J. Hayes and achieving a formal total synthesis of the fascinating alkaloid (-)-Cephalotaxine, Dr. Esmieu simultaneously earned his Master’s (D.E.A.) in organic and bio-organic chemistry at the Université de Haute Alsace and his Diplôme d’Ingénieur from the Ecole Nationale Supérieure de Chimie de Mulhouse in France.
Beginning his career as a scientist the medicinal chemistry department at BioFocus, (later acquired by Charles River), he worked on several disease areas including rheumatoid arthritis, influenza, Usher syndrome, and cystic fibrosis. For the last 6 years, Dr. Esmieu has focused on Huntington’s disease and CNS disorders, with an interest and experience in the emerging field of targeted protein degradation.
He has authored 3 peer-reviewed scientific publications, and been named inventor on 4 patents.